Combo vaccines endorsed by federal advisory panel
In a move that should make it easier for millions of children in the U.S. to get their recommended vaccinations, a federal vaccine advisory panel has endorsed two new combination vaccinations. GlaxoSmithKline won a thumb's up from the advisory panel for a four-in-one shot that guards against diphtheria, tetanus, pertussis and polio at a cost of $45. Sanofi Pasteur won an endorsement of its five-in-one shot for diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b, or HiB. That jab costs $69. The vaccine advisory panel's decision helps clear the way for 36 million children to receive the vaccines through the Vaccines for Children program. Both vaccines have been approved by the FDA.
The new combination vaccines don't change the number of vaccinations that children are expected to receive. But it should make it easier for parents to keep track of which vaccinations have been completed.
- read the report in the Baltimore Sun
Comments
I was employed for many years in Pediatric Care for children at risk, 0-3 yrs. old. Many cases of autism, retardation & seizure were due to chemical reactions to "childhood immunizations". Big Pharm is raking in the money while children are suffering & growing up to be a burden on society because they cannot function as adults thanks to childhood immunizations!
thats a really big statement your making here
there has not been any documented evidence associating thiomersal or mercury content in the vaccines with autism even though there has been a big fuss about it
these vaccines save millions of lives globally lets catharize ourselves on something else ))
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


